Should I buy or sell HLS Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HLTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLTRF, but not buy additional shares or sell existing shares. View HLTRF analyst ratings or view top-rated stocks .

What is HLS Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 1-year price targets for HLS Therapeutics' shares. Their HLTRF share price targets range from $5.00 to $36.00. On average, they predict the company's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 432.5% from the stock's current price. View analysts price targets for HLTRF or view top-rated stocks among Wall Street analysts .

How have HLTRF shares performed in 2024?

HLS Therapeutics' stock was trading at $3.84 on January 1st, 2024. Since then, HLTRF shares have increased by 0.3% and is now trading at $3.85. View the best growth stocks for 2024 here .

Are investors shorting HLS Therapeutics?

HLS Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 2,000 shares, a decrease of 9.1% from the March 15th total of 2,200 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 20.0 days. View HLS Therapeutics' Short Interest .

When is HLS Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HLTRF earnings forecast .

How do I buy shares of HLS Therapeutics?

Shares of HLTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:HLTRF

HLS Therapeutics (HLTRF) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free HLTRF Stock Alerts

$3.85

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.85
▼
$3.85
50-Day Range: $3.11
▼
$4.00
52-Week Range: $2.60
▼
$4.95

Volume: N/A
Average Volume: 1,200 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.50

Stock Analysis Analyst Forecasts Chart Short Interest

Get HLS Therapeutics alerts:

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About HLS Therapeutics Stock (OTCMKTS:HLTRF)

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

HLTRF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HLTRF Stock News Headlines

February 29, 2024 | finance.yahoo.com

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

February 6, 2024 | morningstar.com

HLS Therapeutics Inc

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

December 5, 2023 | finance.yahoo.com

HLS Therapeutics (TSE:HLS) shareholders have endured a 78% loss from investing in the stock three years ago

October 26, 2023 | finance.yahoo.com

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

September 6, 2023 | finance.yahoo.com

HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference

August 10, 2023 | finance.yahoo.com

HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results

June 8, 2023 | marketwatch.com

HLS Therapeutics Chairman to Retire; Polar Nominee to Join Board

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

May 12, 2023 | markets.businessinsider.com

HLS Therapeutics Inc (HLS) Receives a Buy from Clarus

May 3, 2023 | finance.yahoo.com

HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call

April 21, 2023 | finance.yahoo.com

HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 17, 2023 | marketwatch.com

HLS Therapeutics Appoints Craig Millian CEO to Head Company

March 15, 2023 | markets.businessinsider.com

HLS Therapeutics earnings: here's what Wall Street expects

March 2, 2023 | finance.yahoo.com

HLS Therapeutics to Host Q4 and Fiscal 2022 Financial Results Conference Call

January 12, 2023 | finance.yahoo.com

Shareholders in HLS Therapeutics (TSE:HLS) are in the red if they invested three years ago

January 1, 2023 | finance.yahoo.com

HLS Therapeutics Inc. (HLTRF)

December 14, 2022 | finance.yahoo.com

HLS Therapeutics Inc. (TSE:HLS): When Will It Breakeven?

November 10, 2022 | finance.yahoo.com

HLS Therapeutics Announces Q3 Fiscal 2022 Financial Results and Renewal of Normal Course Issuer Bid

October 5, 2022 | benzinga.com

HLS Therapeutics Stock (OTC:HLTRF), Guidance and Forecast

October 3, 2022 | finance.yahoo.com

HLS Therapeutics Announces Updates to its Credit Agreement

April 28, 2022 | finance.yahoo.com

HLS Therapeutics to Host Q1 Fiscal 2022 Financial Results Conference Call

April 26, 2022 | marketwatch.com

HLS Therapeutics Completes Letter of Intent With Canada Alliance on Vascepa

April 26, 2022 | finance.yahoo.com

HLS Therapeutics completes negotiations with pCPA for Vascepa®

March 14, 2022 | finance.yahoo.com

HLS Therapeutics to Host Q4 & Fiscal 2021 Financial Results Conference Call

January 12, 2022 | finance.yahoo.com

HLS Therapeutics to Present at the Sidoti Investor Conference

November 18, 2021 | apnews.com

Saladax Biomedical and HLS Therapeutics Strengthen Partnership With an Exclusive Distribution Agreement for Canada

See More Headlines

Receive HLTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: OTCMKTS:HLTRF
CUSIP: N/A
CIK: N/A
Web: www.hlstherapeutics.com
Phone: 647-495-9000
Fax: N/A
Employees: 91
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.50
High Stock Price Target: $36.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +432.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Jason A. Gross Pharm.D. (Age 59)
Vice President of Scientific Affairs
Comp: $260.75k
Mr. Ryan C. Lennox B.A. (Age 43)
J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary
Comp: $286.58k
Mr. Craig Stuart Millian M.B.A. (Age 56)
CEO & Director
Mr. John Hanna CPA
CGA, M.B.A., Interim CFO & Non-Independent Director
Brian T. Walsh
Senior Vice President of Commercial
Mr. David Spence (Age 56)
VP & Corporate Controller

Key Competitors

View All Competitors

HLTRF Stock Analysis - Frequently Asked Questions

Should I buy or sell HLS Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HLTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLTRF, but not buy additional shares or sell existing shares.
View HLTRF analyst ratings or view top-rated stocks.
What is HLS Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 1-year price targets for HLS Therapeutics' shares. Their HLTRF share price targets range from $5.00 to $36.00. On average, they predict the company's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 432.5% from the stock's current price.
View analysts price targets for HLTRF or view top-rated stocks among Wall Street analysts.
How have HLTRF shares performed in 2024?: HLS Therapeutics' stock was trading at $3.84 on January 1st, 2024. Since then, HLTRF shares have increased by 0.3% and is now trading at $3.85.
View the best growth stocks for 2024 here.
Are investors shorting HLS Therapeutics?: HLS Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 2,000 shares, a decrease of 9.1% from the March 15th total of 2,200 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 20.0 days.
View HLS Therapeutics' Short Interest.

When is HLS Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HLTRF earnings forecast.
How do I buy shares of HLS Therapeutics?: Shares of HLTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HLTRF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial